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Abstract
Background: The feasibility of shared decision making (SDM) for patients with schizophrenia remains controversial
due to the assumed inability of patients to cooperate in treatment decision making. This study evaluated the
feasibility and efficacy of SDM in patients upon first admission for schizophrenia.
Methods: This was a randomized, parallel-group, two-arm, open-label, single-center study conducted in an acute
psychiatric ward of Numazu Chuo Hospital, Japan. Patients with the diagnosis of schizophrenia upon their first
admission were randomized into a SDM intervention group or a usual treatment group in a 1:1 ratio. The primary
outcome was patient satisfaction at discharge. The secondary outcomes were attitudes toward medication at
discharge and treatment continuation at 6 months after discharge.
Results: Twenty-four patients were randomly assigned. The trial was prematurely terminated due to slow
enrollment. At discharge, the mean score on satisfaction was 23.7 in the SDM group and 22.1 in the usual care
group (unadjusted mean difference: 1.6; 95% CI: −5.2 to 2.0). Group differences were not observed in attitude
toward medication and treatment continuation. There was no statistically significant difference between the groups
for the mean Global Assessment of Functioning score at discharge or length of stay as safety endpoint.
Conclusions: No statistical differences were found between the SDM group and usual care group in the efficacy
outcomes and safety endpoints. Large trials are needed to confirm the efficacy of the SDM program upon first
admission for schizophrenia.
Trial registration: The study has been registered with ClinicalTrials.gov as NCT01869660 (registered 27 May, 2013).
Keywords: Shared decision making, SDM, Schizophrenia, Randomized controlled trial, Pilot study, Inpatient treatment
Background
Patient-centered care, where patients and health service
providers establish partnerships to ensure every decision
for patients’ needs and preferences, has been a core
component of modern general medicine [1, 2]. Shared
decision making (SDM) is a model in which patients and
clinicians collaborate together throughout the entire
decision-making process, with information shared and
patients allowed to state their individual preferences [3].
SDM is expected to embody the idea of patient-centered
care in clinical medicine. A meta-analysis found that,
compared with usual care, SDM improves a patients’
knowledge acquisition, confidence, and active participa-
tion in treatment [4].
On the other hand, there has been some controversy
among psychiatrists regarding the feasibility of SDM in
regards to psychiatric treatment, particularly when it
involves the treatment of severe mental illnesses such as
schizophrenia, with respect to patient vulnerability to
paternalism and coercive treatment due to patient symp-
toms such as disorganized thinking and excessive suspi-
cion [5, 6]. Therefore, SDM had not targeted patients
with severe mental illness such as schizophrenia because
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of presumed inability to cooperate in treatment decision
making. Along with the recovery movement, mental
healthcare providers are now encouraged to support
every patient in pursuing their life goals [7]. In addition,
clinical guidelines [8, 9] now advocate the use of SDM
in psychiatry as a patient-centered care.
Nevertheless, there is a lack of evidence of SDM in
patients with severe mental illness. To the best of our
knowledge, only five randomized controlled trials have
assessed the efficacy of SDM in patients with schizo-
phrenia and related disorders [10–14]. Furthermore,
there are serious limitations with the previous studies.
First, only two trials [10, 11] focused on inpatient treat-
ments in which coercive treatments are commonly
administered. Second, all trials, with the exception of
one that assessed long-term adherence and readmission
rates [11], used only soft outcomes such as treatment
satisfaction, perceived involvement in treatment decision
making, and participants’ feelings of empowerment.
Third, no study focused a homogenous sample of
patients who do not have a history of psychiatric
hospitalization. We believe it is important to focus on
patients without prior experience of hospitalization, be-
cause better relationships between patients and medical
providers in the early treatment phase for schizophrenia
lead to better compliance [15].
Additional trials are needed to establish the feasibility
and efficacy of SDM in patients with schizophrenia. We
aimed to evaluate the feasibility and efficacy of SDM in
patients upon first admission for schizophrenia.
Methods
Design overview
Details of the study protocol have been reported elsewhere
[16]. The objective of this study was to evaluate the feasi-
bility and efficacy of an SDM intervention compared to
usual treatment on patient satisfaction at discharge and
treatment continuation 6 months post-discharge for first-
admission patients with schizophrenia. This was an
investigator-initiated, single-center, randomized trial in
which participants were randomly assigned either SDM
plus usual care or usual care. Assessments were com-
pleted at admission, discharge, and 6 months after dis-
charge. The trial was registered at ClinicalTrials.gov
(NCT01869660) on May 27, 2013, and the first patient
was recruited on June 4, 2013, and the last patient com-
pleted follow-up on September 29, 2015. The present
study was originally planned to recruit 58 patients but was
stopped prematurely due to slow patient enrollment. The
institutional review board of the Yokohama City
University, Japan, approved this study (No.: A130321008).
All participants provided written informed consent or, if
the participant was younger than 20 years of age, the legal
guardian provided written informed consent.
Setting and participants
Participants were consecutively recruited from an acute
psychiatric ward of the Numazu Chuo Hospital, located
in Numazu city, Shizuoka, Japan. Numazu Chuo
Hospital is the only psychiatric hospital that receives
emergency admissions for a population of 870,115 in-
habitants. We assessed the following eligibility criteria
within 3 days of admission: patients were aged 16–65
years; had no history of psychiatric admission (first
admission); had a diagnosis of schizophrenia spectrum
disorder (including schizophrenia, schizotypal, and delu-
sional disorders defined according to the diagnosis codes
F20–F29 in the International Statistical Classification of
Diseases, 10th revision [ICD-10]). Exclusion criteria
included moderate to profound mental retardation, or-
ganic mental disorders (ICD-10 codes: F00–F09), inabil-
ity to converse in Japanese, and severe conceptual
disorganization (a score of 5 or more on the Brief
Psychiatric Rating Scale) [17, 18].
Randomization
Randomization was conducted by the central web-based
randomization system after obtaining written informed
consent. Participants were randomly assigned in a 1:1
ratio using a computer-generated random number se-
quence. Assignment was balanced for the stratification
factors of sex, age (younger or older than 20 years of
age), and onset of illness (less or more than 1 year) by
using a minimization method.
Interventions
In the SDM group, participants received the SDM model
program in addition to usual psychiatric inpatient care.
The SDM model program is a 15–20-min weekly inter-
vention during the acute psychiatric ward stay, and its
development has been detailed previously [16]. The
intervention consists of three sequential elements: asses-
sing patient’s perceptions on their on-going treatments by
a self-report questionnaire; sharing patients’ and medical
staffs’ perceptions on the treatments in a 15–20-min
meeting; and patients together with medical staff deciding
on a care plan for the next week. As a medical team, a pri-
mary physician, a primary nurse, and others participated
in the meetings. To improve adherence and quality of the
intervention, independent supervisors managed interven-
tion schedules, facilitated meetings, and educated medical
staff.
In the usual care group, participants received usual
psychiatric inpatient care, which is mainly pharmaco-
logical treatment. During the hospitalization, primary
physicians examined their patients every day and nurses
helped patients by focusing on self-care activities and
the daily activity program. Primary physicians and nurses
usually discussed the patient’s overall progress and plan
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for discharge. However, there was no fixed occasion for
the patient and staff to share all the information. In
addition, there was no certainty that patients would be
introduced to the concept of SDM or that they would be
empowered to actively participate in the treatment.
Patients in both SDM and usual care groups received
treatments by the same medical staff in the ward—15
primary psychiatrists, nurses and three psychiatric social
workers.
Outcomes and follow-up
The primary outcome was patient satisfaction at dis-
charge. Patient satisfaction was assessed using the Japa-
nese version of the Client Satisfaction Questionnaire
(CSQ-8 J), a 8-item self-rated measure [19, 20]. The
CSQ-8 J assesses overall satisfaction with care received
using a four-point Likert scale. Scores range from 8 to
32, with higher values indicating greater satisfaction.
The CSQ-8 J has good internal consistency (Cronbach’s
α = .83) and moderate convergent validity (r = .36–.49)
with the client satisfaction inquiry [21].
Secondary outcomes included attitudes toward medica-
tion at discharge and treatment continuation 6 months
after discharge. Attitudes were assessed using the Japanese
version of the Drug Attitude Inventory-10 (DAI-10), a 10-
item self-rated measure [22, 23]. The DAI-10 assess atti-
tude toward medication using a true-false scale. Scores
range from −10 to 10, with higher values indicating more
positive attitudes. The DAI-10 has good internal
consistency (Cronbach’s α = .97) and adequate test-retest
reliability (r = .81) [23]. Treatment continuation was
assessed by identifying whether a patient received out-
patient psychiatric treatment within 30 days prior to the
follow-up time (i.e., at 6 months after discharge). We iden-
tified information on treatment continuation from med-
ical records if the patient continued treatment at the
Numazu Chuo Hospital or if not, by asking patients with
a telephone call. Symptom severity, as assessed by the
Brief Psychiatric Rating Scales (BPRS) at discharge, was
removed as a secondary outcome as this outcome was in-
correctly specified in the original study protocol (14). We
also amended the protocol to include the Global Assess-
ment of Functioning at discharge [24] and length of stay
as safety endpoints.
Statistical analysis
We estimated unadjusted mean difference (MD) and risk
difference (RD) with their 95% confidence interval (95%
CI) between the groups (SDM vs. usual care) using
Student’s t test for continuous variables (i.e., patient
satisfaction and attitude toward medication) and chi-
squared test for a categorical variable (i.e., treatment
continuation). We also calculated standardized MD and
risk ratio with their 95% confidence interval between the
groups. To control characteristics such as sex, age, dur-
ation of illness, and symptom severity assessed by the
BPRS at admission, we estimated adjusted MD and RD
using a marginal structural binomial model [25]. All data
were analyzed by R version 3.2.0.
Results
Baseline characteristics
A total of 448 patients were screened, of whom 24 were ran-
domly assigned (Fig. 1). The most common reason for ineli-
gibility was a prior history of psychiatric admission (n =
280). After randomization, two patients were lost before out-
come assessments due to hospital transportation and early
discharge without doctors’ permission. Table 1 shows base-
line characteristics in the groups. In general (87% of total of
30 sessions), a primary doctor, a ward nurse, and a facilitator
participated in the SDM meeting. The median number of
sessions received was 3 (range: 2–5).
Outcomes
For the primary and secondary outcomes, group differ-
ences were not observed in both unadjusted and
adjusted analyses (Table 2). At discharge, the mean score
on satisfaction was 23.7 in the SDM and 22.1 in usual
care group (unadjusted MD: 1.6; 95% CI: −5.2 to 2.0).
The mean score of attitudes toward medication was 3.8
in the SDM and 2.3 in usual care group (unadjusted
MD: 1.5; 95% CI: −5.6 to 2.7). At 6 months after dis-
charge, continuation rate was 89% in the SDM group
and 69% in usual care group (unadjusted RD: 19.7; 95%
CI: −12.8 to 52.1). There were no statistically significant
differences between the groups for the mean Global
Assessment of Functioning score at discharge or length
of stay (Table 2).
Discussion
We examined whether our SDM intervention—a complex
intervention including assessment of patient’s perception,
regular meetings, and shared care planning—improved
clinical outcomes for patients with schizophrenia in the
early treatment stage. This pilot study is the first random-
ized controlled trial to evaluate efficacy of SDM targeting
patients with first-admitted schizophrenia. We found no
statistical differences between the SDM group and usual
care group in the primary and secondary outcomes.
Until now, SDM for patients with acute psychosis was
deemed difficult because of the patient’s decisional cap-
acity, time constraints, and coercive atmosphere [26].
Consequently, medical providers have been hesitant
about patient’s active involvement in decision making.
However, in our study, treatment adherence was main-
tained throughout the trial. All cases in the intervention
group could receive interventional SDM sessions, for
20 min per week, for multiple times in spite of acute
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symptoms and busyness at the emergency ward. There
were no statistically significant differences between
groups in safety endpoints. None of the participants
dropped out from the SDM intervention, with the ex-
ception of hospital transportation and early discharge
without a doctor’s permission. These results suggest the
feasibility of SDM in patients with first-admission
schizophrenia.
The strengths of our trial include a high rate of in-
formed consent acquisition, assessment of treatment
continuation after discharge as a hard endpoint, narrow
eligibility criteria of first-admission schizophrenia, and
Fig. 1 Flow diagram. SDM = shared decision making.†Some patients met 1 > criterion
Table 1 Baseline characteristics
Characteristic Total (n = 22) SDM (n = 9) Usual care (n = 13)
Women, n (%) 7 (31.8) 3 (33.3) 4 (30.8)
Mean age at admission (SD), y 39.1 (11.7) 41.6 (13.6) 37.4 (9.8)
At least 1-year after the onset of illness, n (%) 14 (63.6) 7 (77.8) 7 (53.8)
Suicidal ideation, n (%)
Absent 8 (36.4) 3 (33.3) 5 (38.5)
Present 9 (40.9) 5 (55.6) 4 (30.8)
Unknown 5 (22.7) 1 (11.1) 4 (30.8)
Physical comorbidity, n (%) 6 (27.3) 4 (44.4) 2 (15.4)
Mean BPRS score at admission (SD) 57.0 (14.8) 49.6 (14.2) 62.2 (12.9)
Mean GAF score at admission (SD) 17.5 (12.5) 20.9 (17.1) 14.2 (6.4)
Average length of stay (SD), day 66.7 (40.4) 66.5 (17.4) 65.2 (50.5)
BPRS the Brief Psychiatric Rating Scale, GAF the Global Assessment of Functioning scale, SDM shared decision making
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homogeneous quality of interventions supported by the
supervision team. However, this study had several limita-
tions. First, the sample size was too small, as we had
stopped the investigation early due to slow enrollment.
As a result, our trial did not have adequate statistical
power to detect a difference in primary and secondary
outcomes. The primary reason for the slow enrollment
was the narrow eligibility criteria focusing on only those
whom it was their first admission for schizophrenia. Fu-
ture studies should include a longer recruitment period,
conduct a multi-center trial, or use wider eligibility
criteria such as including patients with history of psychi-
atric hospitalization. Second, duration of follow-up
might be too short. A cohort study of discharged
patients with schizophrenia showed that the average
time to discontinuation of antipsychotics after discharge
was 289 days for olanzapine and 254 days for risperi-
done [27]. We might need to set the duration of follow-
up to longer than 6 months to maximize statistical
power. Third, the treatment intensity of SDM was
limited due to not including peers and family in the
intervention. Jönsson et al. [28] considered personal sup-
porters to be essential members of SDM in the treat-
ment of severe mental illness; furthermore, there have
been some attempts in palliative care [29, 30]. Not pro-
viding a post-discharge program is another concern for
the intensity. Fourth, there was a contamination risk be-
cause we conducted the trial in a ward where the same
medical staff could be involved in both SDM and usual
care groups. Thus, patients in usual care were treated by
physicians who received education on the concept of
SDM, although these patients never had an opportunity
to receive the standardized SDM intervention. Lastly, we
did not include any measure of SDM as outcome and
any assessment of fidelity of the intervention; however,
this limitation might not induce bias, because independ-
ent supervisors participated in regular meetings.
Conclusions
This randomized controlled trial suggests that SDM
intervention is feasible during acute inpatient treatment
for schizophrenia. Large trials are needed to confirm the
efficacy of the SDM in patients with schizophrenia.
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Table 2 Primary and secondary outcomes
Outcome SDM Usual care Crude treatment
effect (95% CI)
Adjusted treatment
effect (95% CI)c
Standardized mean
difference/risk ratio (95% CI)
Primary outcome
Mean satisfaction at discharge (SD) 23.7 (3.9) 22.1 (3.7) 1.6 (−5.2 to 2.0)a −0.8 (−4.2 to 2.6)a 0.39 (−0.47 to 1.24)d
Secondary outcomes
Mean attitude toward medication
at discharge (SD)
3.8 (3.7) 2.3 (4.8) 1.5 (−5.6 to 2.7) a −1.1 (−4.4 to 2.3)a 0.31 (−0.55, 1.16)d
Treatment continuation at 6 months
after discharge, n (%)
8 (88.9) 9 (69.2) 19.7 (−12.8 to 52.1)b 22.1 (−24.9 to 70.1)b 0.36 (0.05, 2.72)e
Harm
Mean GAF score at discharge (SD) 55.6 (11.2) 47.8 (18.9) 7.7 (−23.1 to 7.7) 4.0 (−13.0 to 20.0)a 0.44 (−0.42, 1.30)d
Average length of stay (SD), day 66.7 (40.4) 66.5 (17.4) 1.3 (−39.6 to 37.0) −1.7 (−43.6 to 40.9)a 0.03 (−0.82, 0.88)d
BPRS the Brief Psychiatric Rating Scale, CI confidence interval, GAF the Global Assessment of Functioning, SDM shared decision making
aMean difference (95% CI) between the SDM and usual care groups
bRisk difference (95% CI) between the SDM and usual care groups
cAdjusted for sex, age, illness duration, and symptom severity assessed by the BPRS at admission
dStandardized mean difference (95% CI) between the SDM and usual care groups
eRisk ratio (95% CI) between the SDM and usual care groups
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